“Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s91. doi:10.25251/skin.4.supp.91.